Introduction
Each year, approximately 40 000 Americans are aicted with oral cancer (Boring et al., 1992) . It is the sixth most common cancer for both sexes in the overall population of the United States (Wong et al., 1996) . More than 90% of the oral cancers are squamous cell carcinomas (SCCs) (Wong et al., 1996) . Unfortunately, the overall 5-year survival rate for patients diagnosed with oral cancer is only 50%, a percentage which has not changed signi®cantly over the past two decades (Volkes et al., 1993) . In addition to its high mortality rate, oral SCC also has a major functional and cosmetic impact as a result of its location. Clearly there is a need to develop new strategies for the successful treatment of this disease.
The relationship between retinoids and cancer has been known for many years and has been reviewed by several investigators (De Luca, 1991; Gudas et al., 1994; Moon et al., 1994) . Retinoids have been demonstrated to inhibit development of a number of dierent types of tumors (Aylsworth et al., 1986; Munker et al., 1987) and to inhibit the growth of many human tumor cell lines (Wu et al., 1997a (Wu et al., ,b, 1998a Harant et al., 1993; Saunders et al., 1993; Grunt et al., 1992; Somay et al., 1991 Somay et al., , 1992 Cline and Rice, 1983; Kim et al., 1984; Reiss et al., 1985; Thatcher et al., 1985; Rubin and Rice, 1986; Lotan et al., 1987; Sakar and Das, 1988) including squamous cell carcinomas (SCCs) (Cline and Rice, 1983; Kim et al., 1984; Reiss et al., 1985; Thatcher et al., 1985; Rubin and Rice, 1986; Lotan et al., 1987; Sakar and Das, 1988) . Recently, retinoids have been successfully used in vivo to prevent the progression of preneoplastic oral, bronchial, and head-and-neck lesions to frank malignant tumors Benner et al., 1994; Lotan et al., 1995) . While the success of retinoid chemotherapy for oral cancer is clearly documented, the exact molecular mechanism by which retinoids alter growth in oral SCC cells remains to be determined.
Within the last few years tremendous advances have been made in the understanding of the mechanism of action of retinoids. Several nuclear receptors which bind RA (RARs and RXRs) have been cloned (for review, see Mangelsdorf et al., 1994) . Three types of RARs have been identi®ed (RAR-a, RAR-b and RARg) (for review, see Mangelsdorf et al., 1994) . RXR was initially identi®ed as an orphan receptor which required 10 ± 100-fold higher concentrations of all-trans RA than the RARs in transactivation assays. Similar to the RARs, three forms of RXR have been identi®ed (RXR-a, RXR-b and RXR-g). 9-cis RA, an isomer of all-trans RA, has been reported to be a natural ligand for RXR (Heyman et al., 1992; Levin et al., 1992) .
Since the biological eects of retinoids are known to be mediated for the most part via the RARs and RXRs, we set out to determine if modulation of RAR function through the use of either a pan-RAR dominant negative mutant, a conformationally restricted synthetic RAR-g selective agonist or an RAR-g-selective antagonist signi®cantly alters the growth inhibitory response of SCC-25 cells to retinoids. Our results provide strong evidence that RARs play a critical role in mediating the sensitivity of squamous cell carcinoma cells to retinoids.
Results

All-trans-RA inhibits growth of SCC-25 cells
We initially investigated the growth response of the SCC-25 cell line to treatment with various doses of alltrans-RA. SCC-25 cells were derived from a 70-yearold male with squamous cell carcinoma of the tongue. Growth of this SCC-25 cell line is completely independent of ®broblast feeder support. The cell line is hypertriploid and the modal chromosome number is 76 (Rheinwald and Beckett, 1981) . 2610 5 SCC-25 cells were plated in 100 mm dishes with 10 ml of complete DMEM/F-12 medium supplemented with 10% fetal bovine serum, and treated with all-trans-RA at concentrations ranging from 10 710 to 10 76 M. Control cultures were treated with an equal volume of ethanol. Direct cell counting was performed on day 7 after treatment using a hemacytometer. Figure 1 shows that all-trans-RA at concentrations ranging from 10 710 ± 10 76 M signi®cantly inhibits the growth of SCC-25 cells. This growth inhibition is all-trans-RA dosedependent with the maximum inhibition (*35% of control) achieved at a concentration of 10 76 M. The concentration of all-trans-RA required to reduce the growth of SCC-25 cells to 50% of control (IC 50 ) was approximately 5610
78 M. Similar results were obtained when growth was monitored by MTT assay (data not shown). It also should be noted that treatment of SCC-25 cells with all-trans-RA did not induce apoptosis as determined by both viable cell counting and an apoptosis ELISA (data not shown).
Dominant negative mutant RAR-b2(R269Q) was successfully transduced into and overexpressed in human SCC-25 cells
In order to demonstrate a role for RAR/RXR function in the process of growth inhibition by all-trans-RA, we used a retroviral gene transfer system to prepare stable SCC-25 cell clones constitutively overexpressing the mouse dominant negative mutant RAR-b2 (R269Q). In this mutant RAR, arginine 269 is replaced by glutamine (Tairis et al., 1995) . While this mutant receptor has dimerization and DNA binding activity comparable to the wild type RAR-b2, it exhibits a dramatic reduction in ligand binding anity and ligand dependent transcriptional transactivation. We have previously shown that overexpression of this mutant in retinoid sensitive ovarian carcinoma cells reduces the growth inhibitory response to all-trans-RA (Wu et al., 1997b) .
Pooled clones of SCC-25 cells overexpressing mutant RAR-b2(R269Q) or MSCVpac vector transduced SCC-25 cells were selected by resistance to puromycin. RNase protection assay was employed to con®rm the overexpression of mutant RAR-b2(R269Q). The antisense RNA probe was synthesized from a plasmid containing the mouse RAR-b2 speci®c sequence, which recognized the exogenous mouse RAR-b2 but not endogenous human RAR-b2. The results of the RNase protection assay, shown in Figure 2 , demonstrate that the dominant negative mouse mutant RAR-b2 (R269Q) was successfully transduced into and overexpressed in human SCC-25 cells. Since we have previously shown that this mutant eectively blocks the function of wild type RARs, presumably by complexing with wild type RARs and RXR, (Tairis et al., 1995) , we next determined the eects of downregulation of RAR/RXR function on all-trans-RA induced growth inhibition of SCC-25 cells.
Overexpression of dominant negative mutant RAR-b2 (R269Q) alters the sensitivity of SCC-25 cells to all-trans-RA-mediated growth inhibition SCC-25 cells overexpressing mutant RAR-b2 (R269Q) or MSCVpac vector-transduced SCC-25 cells were seeded in 96-well plates at a density of 4000 cells/well. Quadruplicate MTT assays were performed daily with optical density at 590 nm (A 590 ) using a 96-well microplate reader. Figure 3a shows that the growth rate of non-treated RAR-b2 (R269Q)-transduced SCC-25 cells was slightly slower than that of untreated MSCVpac vector-transduced SCC-25 cells. Figure 3b shows that SCC-25 cells overexpressing mutant RARb2 (R269Q) were less sensitive to growth inhibition by all-trans-RA. RAR-b2 (R269Q) SCC-25 cells or MSCVpac SCC-25 cells were treated with all-trans-RA at concentrations ranging from 10 710 ± 10
Control cultures were treated with an equal volume of ethanol. The MTT assay was performed as above on day 7 after treatment. overexpressing mutant RAR-b2 (R269Q) was about 8610 76 M. Since the RAR-b2 (R269Q) mutant has been shown to inhibit RAR/RXR dependent transcriptional activity, these results suggest that reduction of functional RAR/RXR signi®cantly altered the growth inhibitory response of SCC-25 cells to all-trans-RA.
These results were con®rmed by soft agar assay. We found that the eects of this dominant negative mutant were more profound in the soft agar assay than in the MTT assay. RAR-b2 (R269Q) SCC-25 cells or MSCVpac SCC-25 cells were grown at a density of 1610 74 cells in 60 mm dishes with complete medium containing 0.3% agar over a solidi®ed agar base consisting of complete medium containing 0.6% agar. Fifteen days after incubation, the number of colonies containing more than 25 cells were counted using a light microscope. We found that colony formation of non-treated RAR-b2 (R269Q) transduced SCC-25 cells was less than that of MSCVpac vector transduced SCC-25 cells (Figure 4a ). However this did not aect our ability to analyse the eect of all-trans-RA on colony formation since each transduced cell line treated with all-trans-RA would be compared to itself treated with ethanol. Figure Control cultures were treated with an equal volume of ethanol.
MTT assay was performed as above on day 7 after treatment. Data are expressed as the percentage of ethanol control+s.d.
Synthetic RAR-g selective retinoids inhibit growth of SCC-25 cells
In light of previous work by Lotan and colleagues suggesting a potential role for RAR-g in mediating retinoid growth responses in oral SCC cells (Oridate et al., 1996) , we next examined the growth inhibitory activity of RAR-g-selective retinoids. The selectivity of these retinoids for individual RAR subtypes was originally reported by Chao et al. (1997) and Dawson et al. (1998) and is shown in Table 1 . It is clear that at 10 76 M, MM 11254 and MM 11389 selectively activate both RAR-g and RAR-b dependent transcriptional activity but do not activate RAR-a or RXR-a dependent transcription. Since SCC-25 cells contain extremely low levels of RAR-b (Hu et al., 1991 and data not shown), we reasoned that the cross-selectivity of these retinoids for RAR-b should not contribute signi®cantly to the resultant growth inhibitory response of SCC-25 cells. Moreover, the selectivity of these retinoids for RAR-g is substantially greater at 10 77 or 10 78 M (see below). Initially, SCC-25 cells were treated with synthetic retinoids (MM11253, MM11254 or MM11389) at a concentration of 10 76 M for 7 days. Direct cell counting was performed after treatment for 1, 3, 5, and 7 days. The results show that the synthetic RAR-gselective agonists MM11254 and MM11389 signi®-cantly inhibited the growth of SCC-25 cells, while the RAR-g selective antagonist MM11253 alone did not signi®cantly change the growth of SCC-25 cells Figure  5 ).
RAR-g selective antagonist blocks the effect of RAR-g selective agonists in SCC-25 cells
In order to further demonstrate the role of RAR-g function in retinoid-mediated SCC cell growth inhibition, we examined the eect on SCC-25 cells of combining RAR-g selective agonists and an RAR-g selective antagonist (Figure 6 ). SCC-25 cells were treated with either all-trans-RA or one of the synthetic RAR-g selective agonists (MM11254 or MM11389) at a concentration of 10 78 M, with or without the RAR-g selective antagonist (MM11253) at concentrations Figure 6 shows that treatment of SCC-25 cells with the RAR-g antagonist MM11253 reduced the ability of MM11254 and MM11389 to inhibit SCC cell growth. Thus, modulation of RAR function through the use of an RAR-g selective antagonist alters the growth inhibitory response of SCC-25 cells to RAR-g selective agonists. It is interesting to note that MM11253 was unable to inhibit the growth inhibitory response of oral SCC cells to all-trans-RA even at concentrations as high as 10 76 M. This is consistent with the known functional redundancy among RAR subtypes in response to retinoids such as all-trans-RA which can activate RAR-a and RAR-b as well as RAR-g. Alternatively, all-trans-RA could isomerize to another active retinoid metabolite such as 9-cis-RA and thereby induce another growth inhibitory pathway.
Overexpressing dominant negative mutant RAR-b2(R269Q) alters the sensitivity of SCC-25 cells to synthetic retinoid-mediated growth inhibition Since the dominant negative mutant RAR-b2(R269Q) can inhibit the function of all RAR subtypes (Tairis et al., 1995; Wu et al., 1997b) , we next wished to determine the eect of synthetic RAR-g selective retinoids on the growth of SCC-25 cells overexpressing mutant RAR-b2(R269Q) (Figure 7 ). Mutant RARb2(R269Q) SCC-25 cells or MSCVpac SCC-25 cells were plated in 100 mm dishes at a density of 2610 75 cells and treated with 10 76 M of either MM11254 or MM11389. Control cultures were treated with an equal volume of ethanol. Cell counting was performed on days 1, 3 and 5. SCC-25 cells overexpressing mutant RAR-b2(R269Q) become less sensitive than MSCVpac vector transduced SCC-25 cells to growth inhibition following treatment for 1, 3 or 5 days with either of the two synthetic RAR-g-selective agonists, MM11254 (Figure 7a ) or MM11389 (Figure 7b) .
In order to determine the dose-dependent eects of synthetic RAR-g-selective agonists on the mutant cells, RAR-b2(R269Q) SCC-25 cells or MSCVpac SCC-25 cells were treated with either MM11254 or MM11389 at concentrations ranging from 10 710 ± 10 76 M. Control cultures were treated with an equal volume of ethanol. Cell counting was performed on day 5. SCC-25 cells overexpressing mutant RAR-b2(R269Q) were shown to have reduced sensitivity to growth inhibition after treatment for 5 days with either agonist (Figure 7c and d). It should be noted that the substantial reduction in cell number in cells treated with the highest concentration of MM11389 (10 76 M) was most likely due to nonspeci®c toxicity since both empty vector and R269Q expressing SCC-25 cells exhibited this response.
Discussion
Our data have demonstrated for the ®rst time the following information about retinoid mediated growth inhibition of oral SCC cells: (1) RAR dominant negative mutant RAR-b2(R269Q) alters the growth inhibitory response of SCC-25 cells to retinoids, suggesting that inhibition of SCC-25 cell growth by retinoids is dependent on the binding and activation of RARs; (2) Synthetic RAR-g-selective agonists (MM11254 and MM11389) inhibit growth of SCC-25 cells and RAR-g-selective antagonist MM11253 blocks the growth inhibitory ability of RAR-g selective agonists in SCC-25 cells. This indicates that RAR-g can mediate growth inhibition by retinoids in SCC-25 cells. Taken together, these data provide strong evidence that RARs play an important role in mediating the sensitivity of SCC cells to retinoid mediated growth inhibition.
A wide variety of technical approaches including gene knock-outs, antisense, dominant negative mutants and receptor selective agonists and antagonists have been employed to alter functional levels of RARs and RXRs in many other tumor cell model systems. In each case, downregulation of RAR/RXR function leads to resistance to the growth inhibitory eects of retinoids (Lotan et al., 1992; Mangelsdorf et al., 1994; Wu et al., 1997b) . Thus, our observation that modulation of RAR/RXR expression and function determines the growth response of oral SCC cells to retinoids is not surprising. Several studies have examined the expression of RARs in SCC cells. In 1991, studies by Gudas and colleagues (Hu et al., 1991) compared the expression of each of the RAR and RXR subtypes in RARb 51  87  96  10  24  46  2  4  15  RARg  59  75  73  34  80  84  0  5  21  RXRa  0  0  10  10  10  13 711 77 1 *The selectivity of synthetic retinoids was analysed by transcriptional activation assay using a (TREpal) 2 -tk-CAT reporter system. All of the values are expressed as the percentage of 1 mM all-trans-RA activity for RARs and 1 mM 9-cis-RA activity for RXRa a variety of epithelial cells obtained from the oral cavity including cultured human SCCs, normal human epithelial cells, and benign, hyperplastic and hyperkeratotic lesions. These investigators found a dramatic decrease in the expression of RAR-b in the SCC cell lines, although no alteration in the structure or arrangement of the RAR-b gene was detected in the SCC cell DNA by Southern blotting. This observation was con®rmed and extended to biopsy material by Lotan and colleagues (Xu et al., 1994; Lotan et al., 1995) . Using in situ hybridization, these investigators found that RAR-g, RXR-a, and RXR-b levels were comparable in normal, preneoplastic and malignant lesions of the oral cavity. However, RAR-b mRNA was detected in only about one-third of the SCC lesions and one-half of the premalignant lesions compared to 70% of the adjacent normal tissue. Interestingly, treatment of patients with 13-cis-RA for a period of 3 months resulted in an increase in RAR-b expression and a coincident positive clinical response. Similar studies show that this RAR subtype expression is generally not lost in oral SCC but is frequently reduced (Lotan, 1994; Darwiche et al., 1995) . Moreover, Monzon et al. (1997) identi®ed an SCC cell line, designated SCC 12F, which exhibited reduced dierentiation in response to retinoic acid and a corresponding signi®cant reduction in RAR-g expression compared to other SCC cell lines. In addition, Oridate (1996) obtained results similar to ours when they used antisense and overexpression approaches to modulate RAR-g levels in a head-and-neck SCC cell line (SqCC/Y1). Finally, our results are consistent with other synthetic retinoid studies in breast and ovarian tumor cell models which show that activation of individual RARs (rather than activation of all RARs) is sucient to inhibit growth (Bernard et al., 1992; Shao et al., 1995; Wu et al., 1998a) .
While it may be apparent that the growth response of SCC cells to retinoids is mediated by RARs in general and RAR-g in particular, the identi®cation of molecular events downstream of RAR/RXR activation which mediate retinoid growth inhibition must yet be elucidated. Retinoids may alter the expression and activation status of cell cycle regulatory genes in tumor cells (Wilcken et al., 1996) . Alternatively, retinoids may induce tumor cells to dierentiate or undergo apoptosis (Liu et al., 1996; Pellegrini et al., 1995) . We found that there was no morphological or molecular evidence suggesting that all-trans-RA treated SCC-25 cells undergo dierentiation or apoptosis (data not shown). Moreover, we also observed that growth inhibition of SCC-25 cells by all-trans-RA could be reversed if the retinoid was removed from the culture medium (data not shown). Yet another possibility would be inhibition of AP-1 transcriptional activity. AP-1 activity is known to mediate stimulation of cell growth by tumor promoters. We and others have shown that retinoids exhibit anti-AP-1 activity in breast and ovarian carcinoma cells. Moreover, extent of anti-AP-1 activity correlates with ability of all-trans-RA to inhibit tumor cell growth (Soprano et al., 1996) . It will be interesting to determine if retinoids inhibit AP-1 activity in SCC cells.
In conclusion, the inhibition of SCC cell growth by retinoids is dependent on the binding and activation of retinoid nuclear receptors. The ability to modulate RAR function by dominant negative technology or by the use of RAR selective agonists and an antagonist should lead to the elucidation of additional molecular events responsible for mediating growth inhibition in SCC cells by retinoids.
Materials and methods
Cell culture and reagents
The Human SCC-25 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). These cells were cultured in DMEM/F-12 medium, a 1 : 1 mixture of Ham's F-12 and Dulbecco's Modi®ed Eagle's Medium (JRH Biosciences), supplemented with 10% heat-inactivated fetal bovine serum (Sigma), 2 mM L-glutamine (GIBCO ± BRL), 100 u/ml penicillin (MEDIATECH), 100 mg/ml streptomycin (MEDIATECH) and 0.4 mg/ml hydrocortisone (Sigma).
All-trans-RA was kindly provided by Homann LaRoche, Inc. (Nutley, NJ, USA). MM11253 (previously called SR11253), an RAR-g selective antagonist, (2-{(5,6,7,8-tetrahydro -5,5,8,8 -tetramethyl -2 -naphthalenyl) -2-(6 -carboxy-2-naphthalenyl)-1,3-dithiolane; MM11389 (previously called SR11389), an RAR-g selective agonist, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-5-methyl-2-naphthalenylcarboxylic acid and MM11254 (previously called SR11254), an RAR-g selective agonist, E -6 -{ (5 ,6, 7, 8 -tetrahydro -5, 5, 8, 8 -tetramethyl -2 -naphthalenyl) (hydroxyimino) methyl] -2 -naphthalenecarboxylic acid have been described previously (Chao et al., 1997; Sun et al., 1997; Dawson et al., 1998) . All of the synthetic retinoids were prepared at the Molecular Medicine Research Institute (Mountain View, CA, USA). Data supporting the RAR-selectivity of these retinoids for transcriptional activation using a (TREpal) 2 -tk-CAT reporter system are summarized in Figure 1 ). 10 73 M stock solutions of retinoids were prepared in ethanol and stored at 7208C. All procedures involving retinoids were carried out under subdued light. Fresh retinoid stock was prepared every 2 weeks. Control cultures were treated with an equivalent amount of ethanol.
MTT 3-[4,5-dimethylthiazol-2-yl) 2,5-dephenyl-tetrazolium bromide, thiazolyl blue) was purchased from Sigma. The 5 mg/ml stock solution was prepared fresh every month in sterile phosphate buered saline solution (PBS) and sterilized by ®ltration, then stored at 48C in a dark bottle equipped with a tight cap. Puromycin was purchased from Sigma (Cat No., P-8833). The 2.5 mg/ml stock solution was prepared in sterile PBS.
Growth analysis by direct cell counting
2610
75 SCC-25 cells or SCC-25 cells overexpressing mutant RAR-b2(R269Q) were plated in 100 mm dishes with 10 ml of DMEM/F-12 medium, then treated with all-trans-RA at concentrations ranging from 10 710 ± 10 76 M. Control cultures were treated with an equal volume of ethanol. Cell counting assay was performed on day 7 after treatment using a hemacytometer. Data are expressed as the percentage of ethanol control+s.d. For the growth inhibition by synthetic retinoids, 2610 5 SCC-25 or SCC-25 cells overexpressing mutant RAR-b2(R269Q) cells were treated with either synthetic retinoids (MM11253, MM11254 or MM11389) or all-trans-RA at a concentration of 10 76 M for 7 days. Cell counting was performed after treatment for 1, 3, 5, and 7 days using a hemacytometer. Data are expressed as the percentage of ethanol control+s.d.
MTT assay
The MTT assay is based on the spectrophotometric measurement of a blue formazan product formed by reduction of MTT by mitochondrial dehydrogenase in viable cells (Carmichael et al., 1987; Wu et al., 1998b) . MTT assay was performed daily as described previously by Wu et al., 1997a. For the eects of all-trans-RA on SCC-25 cells, SCC-25 cells overexpressing mutant RAR-b2(R269Q) or MSCVpac vector transduced SCC-25 cells were seeded in 96-well plates at a density of 4000 cells/well, and treated with all-trans-RA at concentrations ranging from 10 710 ± 10
Control cultures were treated with an equal volume of ethanol. MTT assay was performed on day 7 after treatment. Data are expressed as the percentage of ethanol control+s.d.
Soft agar assay
For determination of growth in soft agar, SCC-25 cells overexpressing mutant RAR-b2(R269Q) or MSCVpac vector transduced SCC-25 cells were seeded at a density of 1610 4 cells in a 60 mm dish in 2 ml of DMEM/F12 medium, 0.3% agar, and 10% FBS on top of a base agar which consisted of 3 ml of DMEM/F12 medium, 0.6% agar, and 10% FBS. Fifteen days after incubation, the number of colonies containing more than 25 cells were counted under 1006 magni®cation using a light microscope (Lotan et al., 1990; Wu et al., 1997b Treatment with synthetic retinoids 2610 5 SCC-25 cells were plated in 100 mm dishes with 10 ml of DMEM/F-12 medium, then treated with either all-trans-RA or synthetic RAR-g selective agonists (MM11254 or MM11389) at a concentration of 10 78 M; incubated with or without the RAR-g selective antagonist MM11253 at concentrations ranging from 10 710 ± 10 76 M. Cell counting assay was performed on Day 5 using a hemacytometer. Data are expressed as the percentage of ethanol control+s.d.
Retroviral infection
293T cells were transfected with the retrovirus packaging vectors, pHIT60 and pHIT456 (Soneoka et al., 1995) as well as the MSCVpac retroviral vector containing the mouse mutant RAR-b2(R269Q) (Hawley et al., 1994; Pear et al., 1993; Tairis et al., 1995; Wu et al., 1997b) . After transfection for 24 h, the medium was removed and 10 ml of fresh medium added. The viral supernatants were harvested at 48 h after transfection and ®ltered through 0.45 mm ®lters. SCC-25 cells were infected with retrovirus containing mutant RAR-b2(R269Q) or empty MSCVpac vector. The transduced cells were selected by growth in puromycin.
RNA isolation
RNA samples were prepared by using RNAzol B RNA isolation solvent (TEL-TEST, Inc., Friendswood, TX, USA) (Rappolee et al., 1989) . The concentration and purity of the RNA samples was examined by measuring absorbance at 260 and 280 nm. The integrity of RNA samples was checked by loading 2 mg of RNA on a formaldehyde denaturing agarose gel and staining with ethidium bromide (Cosenza et al., 1988; Owen et al., 1987) .
RNase protection assay
Synthesis of the antisense RNA probe was performed as previously described (Harnish et al., 1992; Toscani et al., 1988) . The antisense RNA probe was synthesized from a plasmid containing mouse RAR ± b 2 speci®c sequence (pGEM-3zf-mRAR b 2 ). Brie¯y, the pGEM-3zf-mRAR b 2 plasmid was linearized by EcoRI. For the probe synthesis reaction, 0.5 mg of linearized plasmid, 20 U of SP6 RNA polymerase, and 50 mCi of [ 32 P]-UTP were used. After synthesis of the RNA probe, the DNA template was removed by digestion with RNase-free DNase (RQ1 DNase; Promega). The integrity of the RNA probe was checked by a 5% denaturing mini-PAGE (polyacrylamide gel electrophoresis). The RNase protection assay method has been described previously (Cosenza et al., 1988; Owen et al., 1989; Toscani et al., 1987 Toscani et al., , 1988 Wu et al., 1997b) . 5 mg of each RNA sample were mixed with the RNA probe and incubated at 568C for 16 h. The samples were digested with RNAse A and RNAse T1 (PharMingen International) and then analysed on 7-M urea 5% PAGE. Dried gels were exposed to X-ray ®lm in a cassette with an intensifying screen.
Abbreviations SCC, squamous cell carcinoma; RARs, retinoic acid receptors; RXRs, retinoid X receptors; all-trans-RA, alltrans-retinoic acid; PAGE, polyacrylamide gel electrophoresis.
